Drugs / Cyclophosphamide for Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06641453 | Nov 2024 → Nov 2027 expected | hepatocellular carcinoma | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cyclophosphamide for Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06641453 ↗ |
| Route | Intravenous | “Administered intravenously at a dose of 300-500 mg/m²/day” NCT06641453 ↗ |